(google.com): Drug companies should be forced to publish all their trial data rather than selecting evidence to back up their claims, experts have said. A review of clinical trial results for the anti-depressant Edronax (reboxetine) showed pharmaceutical firms did not publish most of the data for the drug.
Category: Articles
Click here